froniglutide

Glymera (froniglutide, code name PB1023) is a recombinant glucagon-like peptide-1 (GLP-1) analogue developed as a long-acting GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. It is designed to provide once-weekly subcutaneous dosing and aims to improve glycemic control by reducing fasting plasma glucose and hemoglobin A1c (HbA1c). The drug leverages PhaseBio’s ELP technology to control absorption rate and extend half-life, potentially resulting in improved gastrointestinal tolerability compared to other GLP-1 analogues. Clinical trials have demonstrated significant reductions in fasting glucose and average daily glucose with favorable safety and tolerability profiles. Glymera was investigated in phase 2b clinical trials for adults with type 2 diabetes inadequately controlled by diet, exercise, or oral antidiabetic agents[1][4][5][7].

Brand names

Glymera

Other names

PB1023PB-1023PB 1023froniglutide